Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528893 | 0.91 | F2 (0.33) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL23528923 | 0.88 | RXRB (0.40) | SSTR5HSD17B10CA1CA2 | |
| SCHEMBL736544 | 0.87 | HSD17B10 (0.37) | NPC1RAB9AATMCASP3SENP8 | |
| SCHEMBL28639154 | 0.87 | NPC1 (0.37) | NPC1RAB9AATMCASP3SENP8 | |
| SCHEMBL30309340 | 0.85 | NPC1 (0.36) | NPC1RAB9AATMCASP3SENP8 | |
| SCHEMBL16681006 | 0.83 | HSD17B10 (0.36) | NPC1RAB9AATMCASP3SENP8 | |
| SCHEMBL23536894 | 0.81 | HDAC4 (0.30) | — | |
| SCHEMBL23547904 | 0.81 | HDAC4 (0.30) | — | |
| SCHEMBL23536892 | 0.81 | HDAC4 (0.30) | — | |
| SCHEMBL29948767 | 0.81 | HDAC4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070879-A1 | ISOXAZOLINE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2026-03-12 | — | — | US | disclosed |
| US-12497370-B2 | Isoxazoline derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2025-12-16 | — | — | US | disclosed |
| CN-120004816-A | Isoxazoline derivatives | 礼蓝动物保健有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-115210221-B | Isoxazoline derivatives as pesticides | 礼蓝动物保健有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4077286-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | Elanco Tiergesundheit AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127188-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | ELANCO TIERGESUNDHEIT AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-20210188789-A1 | ISOXAZOLINE DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497370-B2 | Isoxazoline derivatives | CYP3A7, CYP4X1, CYP2A7 | NPC1 2587/4885RAB9A 1183/4885ATM 3221/4885 |
| US-20260070879-A1 | ISOXAZOLINE DERIVATIVES | CHRM1, CBR3, AFF1 | NPC1 1078/4885RAB9A 1217/4885ATM 3132/4885 |
| US-20210188789-A1 | ISOXAZOLINE DERIVATIVES | CYP3A7, CYP4X1, SIRT7 | NPC1 2405/4885RAB9A 850/4885ATM 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.